Navigation Links
Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
Date:12/27/2011

not limited to, uncertainties relating to: the future use and adoption of the CHEMOSAT system by the J.W. Goethe University Hospital,  future initial launch and training agreements with other cancer centers in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
2. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
3. Delcath to Present at the Lazard Healthcare Conference on November 15
4. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
5. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
6. FDA Schedules Delcath Pre-New Drug Application Meeting Date
7. Delcath Announces Completion of Regulatory Notification Process in New Zealand
8. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
9. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
10. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
11. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... June 3 ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... the Jefferies 2010 Global Life Sciences Conference at 4:00 P.M. ET ... the Grand Hyatt in New York City . , ... Mr. Roberts also will present at the ThinkEquity Healthcare Conference ...
... , LOUISVILLE, Colo. , June 3 ... cost medical devices will be the topic of a breakout ... Conference and Exhibition. Corey Smith , executive director of ... "Your Mission: To Reduce Costs. Your Challenge: Control!" at ...
Cached Medicine Technology:ViroPharma to Participate in Two June Healthcare Investor Conferences 2Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition 2Gaining Visibility and Control Over Purchases of Medical Devices is the Focus of a GHX Presentation at Premier Annual Breakthroughs Conference and Exhibition 3
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Pregnant women who ... premature or low birth weight babies, a new study suggests. ... Vancouver, Canada, and found that expectant mothers who lived in ... had a 20 percent lower risk of very preterm birth ... moderate preterm birth (30 to 36 weeks). Babies born ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2
... , SANTA ROSA, Calif., Sept. 21 Osseon ... cement delivery needle) and Osseoflex DR (steerable and curvable bone ... for marketing and clinical use in the European Union. , ... FDA approval in the United States, and allows for the ...
... , PEMBROKE, Bermuda, Sept. 21 ... announced today that Linda,McSmith, AVP, Risk Management for Allied World ... Allied World, at the Ohio Association of,Ambulatory Surgery Centers (OAASC) ... September 24-25, 2009. , Ms. McSmith,s ...
... , , , ... Inc. ("Astellas"), in partnership with the National Science Teachers Association ... science teachers to participate in the 2009 NSTA New Science ... to a range of tools and resources, while providing the ...
... , , PHILADELPHIA and LONDON, Sept. 21 ... that provides a unique combination of competitive intelligence and sales forecast ... of pipeline and marketed drugs . The product will be ... on October 8 and 9, and Bio Europe 2009 in Vienna ...
... N.C. The Defense Advanced Research Projects Agency (DARPA), the ... Duke University $19.5 million for an effort led by the ... a portable, easy-to-use diagnostic device that can reveal who is ... or sneeze. DARPA is interested in such a ...
... research and real world operation of electronic medical ... have developed, tested and are now operating innovative ... evidence-based medical information between clinical sources and public ... new tools developed by the Regenstrief Institute that ...
Cached Medicine News:Health News:Osseon Receives CE Mark 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:Thomson Reuters Launches Thomson Pharma Partnering Forecast 2Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Fighting disease outbreaks with 2-way health information exchange 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: